Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles

Pankaj Kumar*, Caitlin Boyne, Sydney Erin Brown, Ayesha Qureshi, Peter Jacob Thorpe, Silvia Anna Synowsky, Sally Lorna Shirran, Simon John Powis*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)


The recent success of monoclonal antibody checkpoint inhibitor therapies that enhance the ability of CD8+ T cells to detect cancer-related antigenic peptides has refocused the need to fully understand the repertoire of peptides being presented to the immune system. Whilst the peptide ligandome presented by cell surface human leucocyte antigen class I (HLA-I) molecules on cancer cells has been studied extensively, the ligandome of extracellular vesicles (EVs) remains poorly defined. Here we report the HLA-I ligandome of both the cell surface and EVs from eight breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, HCC 1806, HCC 1395, and HCC 1954), and additionally the melanoma cell line ESTDAB-056 and the multiple myeloma line RPMI 8226. Utilising HLA-I immunoisolation and mass spectrometry, we detected a total of 6574 peptides from the cell surface and 2461 peptides from the EVs of the cell lines studied. Within the EV HLA-I ligandome, we identified 150 peptides derived from tumour associated antigenic proteins, of which 19 peptides have been shown to elicit T cell responses in previous studies. Our data thus shows the prevalence of clinically relevant tumour-associated antigenic peptides in the HLA-I ligandome presented on EV.
Original languageEnglish
Article number13471
Pages (from-to)249-264
Number of pages15
Issue number2
Early online date20 Apr 2022
Publication statusPublished - 1 Jun 2022


  • Extracellular vesicles
  • Tumour associated antigen (TAA)
  • HLA ligandome
  • T-cell epitopes
  • Breast cancer


Dive into the research topics of 'Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles'. Together they form a unique fingerprint.

Cite this